Premium
Plasma levels of 15d‐PGJ 2 are not altered in multiple sclerosis
Author(s) -
Comabella M.,
Pradillo J. M.,
Fernández M.,
Río J.,
Lizasoain I.,
Julià E.,
Moro M. A.,
SastreGarriga J.,
Montalban X.
Publication year - 2009
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2009.02696.x
Subject(s) - multiple sclerosis , medicine , cerebrospinal fluid , prostaglandin d2 , disease , receptor , immunology
Background: The 15‐deoxi delta prostaglandin J 2 (15d‐PGJ 2 ) is a peroxisome proliferator‐activated receptor‐gamma agonist with potent anti‐inflammatory properties. It has been suggested that 15d‐PGJ 2 may modulate multiple sclerosis (MS). Methods: Here, we investigated the plasma levels of 15d‐PGJ 2 by enzyme‐linked immunoassay in 28 healthy controls and 140 MS patients [30 patients with primary‐progressive MS, 28 patients with secondary‐progressive MS, and 82 patients with relapsing‐remitting MS (28 patients during clinical remission, 25 patients during relapse, and 29 treated with interferon‐beta – IFN‐β)]. Results: Levels of 15d‐PGJ 2 were similar between healthy controls and untreated MS patients with different clinical courses of the disease. Treatment with IFN‐β had no effect on levels of 15d‐PGJ 2 . Conclusions: Although these findings suggest that 15d‐PGJ 2 is not involved in the acute or chronic phases of the disease, further studies measuring 15d‐PGJ 2 in cerebrospinal fluid samples are needed before excluding a role of 15d‐PGJ 2 in MS.